论文部分内容阅读
目的 探讨腹腔联合静脉化疗与单纯静脉化疗对晚期卵巢癌的疗效及毒副反应。方法回顾性分析76例晚期卵巢癌临床资料,包括化疗的途径及疗程数与临床分期、病理类型、组织分级及生存期的关系。其中腹腔联合静脉化疗组(腹化组)36例和单纯静脉化疗组(静脉组)40例。对两组患者疗效及毒副作用进行对比分析。结果76例晚期卵巢癌2年生存率为53.95%,5年生存率为34.21%。术后化疗>6个疗程的5年生存率47.06%,<6个疗程的5年生存率8.0%(P<0.01)。两组间疗效无显著性差异,腹化组严重毒副作用发生率较静脉组明显降低(P<0.05)。结论晚期卵巢癌的预后与临床分期、病理组织分级及化疗疗程数相关,腹腔联合静脉化疗治疗晚期卵巢癌能明显减少药物毒副反应,并且达到与单纯静脉化疗相同的疗效。
Objective To investigate the efficacy and side effects of intraperitoneal combined with intravenous chemotherapy and simple intravenous chemotherapy in advanced ovarian cancer. Methods A retrospective analysis of 76 cases of advanced ovarian cancer clinical data, including the way of chemotherapy and the number of courses and clinical stage, pathological type, histological grade and survival of the relationship. Among them, 36 patients in the abdominal cavity combined with intravenous chemotherapy group (ventral group) and 40 patients in the simple intravenous chemotherapy group (vein group). The two groups of patients efficacy and toxicity were compared. Results 76 cases of advanced ovarian cancer 2-year survival rate was 53.95%, 5-year survival rate was 34.21%. Postoperative chemotherapy> 6-year 5-year survival rate was 47.06%, <6-course 5-year survival rate was 8.0% (P <0.01). There was no significant difference between the two groups. The incidence of severe side effects in the ventral group was significantly lower than that in the vein group (P <0.05). Conclusions The prognosis of advanced ovarian cancer is related to the clinical stage, pathological grade and the number of chemotherapy regimens. Intraperitoneal chemotherapy combined with intravenous chemotherapy can significantly reduce the side effects of drugs and achieve the same therapeutic effect as intravenous chemotherapy alone.